vs
Vita Coco Company, Inc.（COCO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Vita Coco Company, Inc.的1.2倍（$219.9M vs $179.8M），Vita Coco Company, Inc.净利率更高（17.0% vs -1.0%，领先18.0%），Vita Coco Company, Inc.同比增速更快（37.3% vs 2.0%），过去两年Vita Coco Company, Inc.的营收复合增速更高（11.7% vs 8.0%）
唯他可可（Vita Coco）是美国知名饮料企业，主打椰子水产品，是全球椰子水及植物基饮品赛道的头部品牌。截至2016年业务已覆盖31个国家，属于共益企业，由All Market Inc.控股。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
COCO vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$179.8M
营收增速更快
COCO
高出35.3%
2.0%
净利率更高
COCO
高出18.0%
-1.0%
两年增速更快
COCO
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $179.8M | $219.9M |
| 净利润 | $30.5M | $-2.2M |
| 毛利率 | 39.9% | 71.1% |
| 营业利润率 | 18.7% | 0.2% |
| 净利率 | 17.0% | -1.0% |
| 营收同比 | 37.3% | 2.0% |
| 净利润同比 | 61.4% | 92.4% |
| 每股收益（稀释后） | $0.50 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COCOOFIX
| Q1 26 | $179.8M | — | ||
| Q4 25 | $127.8M | $219.9M | ||
| Q3 25 | $182.3M | $205.6M | ||
| Q2 25 | $168.8M | $203.1M | ||
| Q1 25 | $130.9M | $193.6M | ||
| Q4 24 | $127.3M | $215.7M | ||
| Q3 24 | $132.9M | $196.6M | ||
| Q2 24 | $144.1M | $198.6M |
净利润COCOOFIX
| Q1 26 | $30.5M | — | ||
| Q4 25 | $5.5M | $-2.2M | ||
| Q3 25 | $24.0M | $-22.8M | ||
| Q2 25 | $22.9M | $-14.1M | ||
| Q1 25 | $18.9M | $-53.1M | ||
| Q4 24 | $3.4M | $-29.1M | ||
| Q3 24 | $19.3M | $-27.4M | ||
| Q2 24 | $19.1M | $-33.4M |
毛利率COCOOFIX
| Q1 26 | 39.9% | — | ||
| Q4 25 | 34.9% | 71.1% | ||
| Q3 25 | 37.7% | 72.2% | ||
| Q2 25 | 36.3% | 68.7% | ||
| Q1 25 | 36.7% | 62.8% | ||
| Q4 24 | 32.5% | 69.0% | ||
| Q3 24 | 38.8% | 68.7% | ||
| Q2 24 | 40.8% | 67.8% |
营业利润率COCOOFIX
| Q1 26 | 18.7% | — | ||
| Q4 25 | 8.0% | 0.2% | ||
| Q3 25 | 15.3% | -8.3% | ||
| Q2 25 | 14.9% | -7.9% | ||
| Q1 25 | 14.7% | -25.2% | ||
| Q4 24 | 3.4% | -5.3% | ||
| Q3 24 | 15.5% | -9.6% | ||
| Q2 24 | 20.8% | -12.5% |
净利率COCOOFIX
| Q1 26 | 17.0% | — | ||
| Q4 25 | 4.3% | -1.0% | ||
| Q3 25 | 13.2% | -11.1% | ||
| Q2 25 | 13.6% | -6.9% | ||
| Q1 25 | 14.4% | -27.4% | ||
| Q4 24 | 2.6% | -13.5% | ||
| Q3 24 | 14.5% | -13.9% | ||
| Q2 24 | 13.2% | -16.8% |
每股收益（稀释后）COCOOFIX
| Q1 26 | $0.50 | — | ||
| Q4 25 | $0.10 | $-0.05 | ||
| Q3 25 | $0.40 | $-0.57 | ||
| Q2 25 | $0.38 | $-0.36 | ||
| Q1 25 | $0.31 | $-1.35 | ||
| Q4 24 | $0.06 | $-0.76 | ||
| Q3 24 | $0.32 | $-0.71 | ||
| Q2 24 | $0.32 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.9M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $352.2M | $450.0M |
| 总资产 | $488.3M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资COCOOFIX
| Q1 26 | $201.9M | — | ||
| Q4 25 | $196.9M | $82.0M | ||
| Q3 25 | $203.7M | $62.9M | ||
| Q2 25 | $167.0M | $65.6M | ||
| Q1 25 | $153.6M | $58.0M | ||
| Q4 24 | $164.7M | $83.2M | ||
| Q3 24 | $156.7M | $30.1M | ||
| Q2 24 | $150.1M | $26.4M |
总债务COCOOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益COCOOFIX
| Q1 26 | $352.2M | — | ||
| Q4 25 | $331.5M | $450.0M | ||
| Q3 25 | $323.7M | $442.5M | ||
| Q2 25 | $296.9M | $458.3M | ||
| Q1 25 | $277.9M | $458.3M | ||
| Q4 24 | $258.8M | $503.1M | ||
| Q3 24 | $252.1M | $525.9M | ||
| Q2 24 | $232.0M | $546.0M |
总资产COCOOFIX
| Q1 26 | $488.3M | — | ||
| Q4 25 | $461.2M | $850.6M | ||
| Q3 25 | $461.3M | $832.6M | ||
| Q2 25 | $421.1M | $837.2M | ||
| Q1 25 | $384.0M | $823.1M | ||
| Q4 24 | $362.4M | $893.3M | ||
| Q3 24 | $353.1M | $867.9M | ||
| Q2 24 | $323.0M | $882.0M |
负债/权益比COCOOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流COCOOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-3.9M | $27.7M | ||
| Q3 25 | $39.1M | $12.4M | ||
| Q2 25 | $21.8M | $11.6M | ||
| Q1 25 | $-9.8M | $-18.4M | ||
| Q4 24 | $6.9M | $23.7M | ||
| Q3 24 | $9.3M | $11.7M | ||
| Q2 24 | $26.9M | $9.0M |
自由现金流COCOOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-7.1M | $16.8M | ||
| Q3 25 | $35.6M | $2.5M | ||
| Q2 25 | $20.9M | $4.5M | ||
| Q1 25 | $-10.4M | $-25.1M | ||
| Q4 24 | $6.8M | $15.2M | ||
| Q3 24 | $8.9M | $6.3M | ||
| Q2 24 | $26.6M | $-360.0K |
自由现金流率COCOOFIX
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | 7.6% | ||
| Q3 25 | 19.6% | 1.2% | ||
| Q2 25 | 12.4% | 2.2% | ||
| Q1 25 | -7.9% | -13.0% | ||
| Q4 24 | 5.3% | 7.0% | ||
| Q3 24 | 6.7% | 3.2% | ||
| Q2 24 | 18.5% | -0.2% |
资本支出强度COCOOFIX
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 4.9% | ||
| Q3 25 | 1.9% | 4.8% | ||
| Q2 25 | 0.6% | 3.5% | ||
| Q1 25 | 0.4% | 3.5% | ||
| Q4 24 | 0.1% | 4.0% | ||
| Q3 24 | 0.3% | 2.7% | ||
| Q2 24 | 0.2% | 4.7% |
现金转化率COCOOFIX
| Q1 26 | — | — | ||
| Q4 25 | -0.70× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | -0.52× | — | ||
| Q4 24 | 2.05× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 1.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
